Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
Venetoclax monotherapy is effective in 40% of t(11:14) positive multiple myeloma (MM). Here, the authors show that electron transport chain complex I (CI) and complex II (CII) activity predict MM sensitivity to venetoclax, and inhibition of CI with IACS-010759 or CII with TTFA increase sensitivity.
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2020-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-15051-z |